Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 11/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532017 | 0.89 | AGTR1 (0.55) | AGTR1AGTR2FOLH1DHODHLTB4R | |
| SCHEMBL6859807 | 0.89 | AGTR1 (0.69) | AGTR1AGTR2 | |
| SCHEMBL9527916 | 0.89 | AGTR1 (0.53) | AGTR1AGTR2FOLH1LTB4RLTB4R2 | |
| SCHEMBL9528290 | 0.84 | AGTR1 (0.49) | AGTR1AGTR2FOLH1LTB4RLTB4R2 | |
| SCHEMBL9532478 | 0.84 | AGTR1 (0.54) | AGTR1AGTR2FOLH1DHODHLTB4R | |
| SCHEMBL9736561 | 0.84 | AGTR1 (0.55) | AGTR1AGTR2FOLH1DHODHLTB4R | |
| SCHEMBL9528902 | 0.83 | AGTR1 (0.49) | AGTR1AGTR2FOLH1DHODH | |
| SCHEMBL9738059 | 0.83 | AGTR1 (0.50) | AGTR1AGTR2FOLH1DHODHLTB4R | |
| SCHEMBL9738055 | 0.83 | AGTR1 (0.50) | AGTR1AGTR2FOLH1DHODHLTB4R | |
| SCHEMBL6005987 | 0.81 | AGTR1 (0.73) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132437-B2 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | G.D. SEARLE & CO., | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220245-A1 | for example, methyl 4'-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl][1,1'-biphenyl]-2-carboxylate; for treatment of congestive heart failure | GLS, AGTR1, AGTR2 | AGTR1 2/4885AGTR2 3/4885FOLH1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.